問卷

TPIDB > Search Result

Search Result

篩選

List

53Cases

2020-03-17 - 2024-05-02

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2021-04-20 - 2024-07-02

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2021-05-01 - 2025-12-31

Phase II/III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
14Sites

Recruiting12Sites

2021-05-18 - 2023-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2022-06-01 - 2024-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
  • Condition/Disease

    Sacroiliac Joint Pain

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
14Sites

Recruiting14Sites

2024-08-01 - 2028-12-31

Others

Active
A multi-center, prospective study to observe the safety, tolerability, and efficacy of Remodulin® in patients with pulmonary arterial hypertension
  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    Remodulin

Participate Sites
9Sites

Recruiting9Sites

2023-12-15 - 2028-06-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-03-01 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
20Sites

Not yet recruiting11Sites

Recruiting8Sites

2024-05-01 - 2028-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites